Radioactive I-Labeled Larotrectinib for Tumor Imaging and Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective means to trace the distribution of Larotrectinib in the human body and monitor the status of solid tumors in vivo, making it difficult to intuitively determine the physiological functions of Larotrectinib and evaluate its curative and prognostic effects.
Innovation Solution
A radioactive I-labeled Larotrectinib compound is developed, specifically labeled with iodine isotopes (123, 124, 125, 131I), along with a synthesis method for its intermediates, allowing for the creation of a radioactive tumor imaging agent that can be used for specific tumor imaging and potentially synergistic tumor radiotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Larotrectinib is used as a therapeutic drug, then tumor growth inhibition is achieved, but the ability to trace drug distribution and monitor tumor status in vivo is lost
Solution Approach 1:
The patent combines the therapeutic function of Larotrectinib with the imaging function of radioactive iodine labels to create a dual-functional molecule. The radioactive I-labeled Larotrectinib compound simultaneously inhibits TRK signaling pathways to suppress tumor growth and emits detectable radiation signals for real-time tracking of drug distribution and tumor status, thereby resolving the contradiction between therapeutic efficacy and imaging capability.
Solution Approach 2:
The radioactive I-labeled Larotrectinib compound serves multiple functions: it acts as a TRK inhibitor for cancer therapy, a radiotracer for PET/SPECT imaging, and a potential theranostic agent. This multi-functionality allows a single compound to provide both treatment and diagnostic monitoring, eliminating the need for separate therapeutic and imaging agents.
2Measurement precision
If radioactive I-labeled Larotrectinib compound is synthesized, then imaging capability is improved, but synthesis complexity increases
Solution Approach 1:
The synthesis process is divided into distinct modular stages: (1) preparation of the Larotrectinib precursor with appropriate functional groups for radioiodination, (2) radioiodination reaction using I-123, I-124, I-125, I-130, or I-131, and (3) purification and quality control. This segmentation allows each step to be optimized independently and facilitates implementation in different radiopharmacy settings.
Solution Approach 2:
The patent employs a specially designed precursor compound as an intermediary that contains a leaving group (such as triflate or tosylate) at the position where iodine will be incorporated. This intermediary precursor facilitates the radioiodination reaction by enabling efficient nucleophilic substitution with radioactive iodide ions, thereby simplifying the overall synthesis process and improving radiochemical yield.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The radioactive I-labeled Larotrectinib compound enables visualization of its distribution and effectiveness within tumors using PET-CT or SPECT imaging, providing a high-yield, high-specific-activity imaging agent for early tumor diagnosis and treatment monitoring.
Implementation Method 1
A radioactive I-labeled Larotrectinib compound having the following structural formula and its analogs: where R1 and R2 are respectively H, F, Cl, Br, 123I, 124I, 125I, 130I or 131I
Implementation Method 2
the distribution of Larotrectinib online in the human body and the status of solid tumors in vivo
Data Source
AI summary
The invention relates to a radioactive I-labeled Larotrectinib compound and a preparation method and application thereof, including a radioactive I-labeled Larotrectinib compound having the following structural formula and its analogs:where R1 and R2 are respectively H, F, Cl, Br, 123I, 124I, 125I, 130I or 131I, and at least one of R1 and R2 is a radioactive iodine element. The invention provides a preparation method of a radioiodinated pyrazolo[1,5-a]pyrimidine compound base. Radioiodinated pyrazolo[1,5-a]pyrimidine compounds with long half-life and different ray energy can be used for PET tomography and clinical diagnostic research of SPECT. Moreover, the high-energy radioiodinated pyrazolo[1,5-a]pyrimidine can act as a TrK receptor ligand to inhibit the activity of TRK and kill tumor cells; and due to high-energy I-131 ray energy carried, the radioiodinated pyrazolo[1,5-a]pyrimidine can coordinate to shoot tumor cells and thus achieve an accurate radiotherapy effect.